Prostatype Genomics: Updated outlook - Redeye

The next US step is to sign a certified lab partner. In Europe, the company has secured partners in the Nordics and the Iberian Peninsula (Spain and Portugal). Prostatype closed a new share issue amounting to SEK 24m before costs in May. We are updating our base case reflecting the recent right issue and an updated outlook. Our updated view is a base case valuation of SEK 0.90 and a Bull Case of SEK 1.80 and a Bear Case of SEK 0.10. Our Base case includes an additional fund raising within twelve months.

Länk till analysen i sin helhet: https://www.redeye.se/research/915246/prostatype-genomics-updated-outlook?utm_source=finwire&utm_medium=RSS